Abstract
This article reviews the interactions between gut microbiota and cancer immunotherapies and discusses microbiota-based patient stratification strategies such as the prediction of response and the early recognition of toxic events. Additionally, it explores the emerging potential of microbiotherapy to enhance anti-neoplastic efficacy and alleviate toxicity, with the ultimate goal of developing personalized treatment regimens for patients with hepatocellular carcinoma (HCC).